A Study of Itacitinib (INCB039110) in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Investigator: Swaminathan Iyer, MD

Study Coordinator: Karen Woodard

Status: Enrolling

ClinicalTrials.gov Number: NCT02760485

Phone: 713.441.4332

IRB Number: Pro00015423


The purpose of this study is to evaluate the safety/tolerability and efficacy of itacitinib in combination with ibrutinib in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
More to Explore